Back to Directory
Galytx
North West England
Founded 2023
Galectin-3 targeted small molecule therapeutics for cancer and fibrosis
Galytx is a University of Liverpool spin-out developing small molecule therapeutic drugs that target galectin-3, a protein closely associated with cancer, fibrosis and inflammatory disease.
The company's portfolio includes a repurposed clinical-stage asset with an established safety record, alongside pre-clinical compounds intended for injectable use.
Galytx licenses its galectin-3 inhibitors to partner companies for development across specific disease indications, including an exclusive agreement with a Quodria to develop a topical treatment for atopic dermatitis.